ATE250412T1 - Muskarinische antagonisten zur behandlung von presbyopie - Google Patents
Muskarinische antagonisten zur behandlung von presbyopieInfo
- Publication number
- ATE250412T1 ATE250412T1 AT99937295T AT99937295T ATE250412T1 AT E250412 T1 ATE250412 T1 AT E250412T1 AT 99937295 T AT99937295 T AT 99937295T AT 99937295 T AT99937295 T AT 99937295T AT E250412 T1 ATE250412 T1 AT E250412T1
- Authority
- AT
- Austria
- Prior art keywords
- presbyopia
- treatment
- muscarinic antagonists
- cholinergic
- restore
- Prior art date
Links
- 229940121948 Muscarinic receptor antagonist Drugs 0.000 title 1
- 239000003149 muscarinic antagonist Substances 0.000 title 1
- 201000010041 presbyopia Diseases 0.000 title 1
- 230000004308 accommodation Effects 0.000 abstract 1
- 230000001713 cholinergic effect Effects 0.000 abstract 1
- 230000001886 ciliary effect Effects 0.000 abstract 1
- 230000003247 decreasing effect Effects 0.000 abstract 1
- 239000000472 muscarinic agonist Substances 0.000 abstract 1
- 230000001734 parasympathetic effect Effects 0.000 abstract 1
- 230000000284 resting effect Effects 0.000 abstract 1
- 230000036977 tonic contraction Effects 0.000 abstract 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/4164—1,3-Diazoles
- A61K31/4178—1,3-Diazoles not condensed 1,3-diazoles and containing further heterocyclic rings, e.g. pilocarpine, nitrofurantoin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/695—Silicon compounds
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/21—Esters, e.g. nitroglycerine, selenocyanates
- A61K31/215—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids
- A61K31/22—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids of acyclic acids, e.g. pravastatin
- A61K31/221—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids of acyclic acids, e.g. pravastatin with compounds having an amino group, e.g. acetylcholine, acetylcarnitine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/21—Esters, e.g. nitroglycerine, selenocyanates
- A61K31/27—Esters, e.g. nitroglycerine, selenocyanates of carbamic or thiocarbamic acids, meprobamate, carbachol, neostigmine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
- A61K31/34—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having five-membered rings with one oxygen as the only ring hetero atom, e.g. isosorbide
- A61K31/341—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having five-membered rings with one oxygen as the only ring hetero atom, e.g. isosorbide not condensed with another ring, e.g. ranitidine, furosemide, bufetolol, muscarine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/445—Non condensed piperidines, e.g. piperocaine
- A61K31/4453—Non condensed piperidines, e.g. piperocaine only substituted in position 1, e.g. propipocaine, diperodon
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/445—Non condensed piperidines, e.g. piperocaine
- A61K31/452—Piperidinium derivatives
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
- A61K31/551—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole having two nitrogen atoms, e.g. dilazep
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
- A61K31/551—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole having two nitrogen atoms, e.g. dilazep
- A61K31/5513—1,4-Benzodiazepines, e.g. diazepam or clozapine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/02—Drugs for disorders of the nervous system for peripheral neuropathies
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
- A61P27/10—Ophthalmic agents for accommodation disorders, e.g. myopia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
Landscapes
- Health & Medical Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Life Sciences & Earth Sciences (AREA)
- Epidemiology (AREA)
- Emergency Medicine (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Organic Chemistry (AREA)
- Engineering & Computer Science (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Biomedical Technology (AREA)
- Neurology (AREA)
- Neurosurgery (AREA)
- Ophthalmology & Optometry (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US09/126,064 US6291466B1 (en) | 1998-07-30 | 1998-07-30 | Cholinergic agents in the treatment of presbyopia |
| PCT/US1999/016260 WO2000006135A2 (en) | 1998-07-30 | 1999-07-22 | Cholinergic agents in the treatment of presbyopia |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| ATE250412T1 true ATE250412T1 (de) | 2003-10-15 |
Family
ID=22422802
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| AT99937295T ATE250412T1 (de) | 1998-07-30 | 1999-07-22 | Muskarinische antagonisten zur behandlung von presbyopie |
Country Status (12)
| Country | Link |
|---|---|
| US (2) | US6291466B1 (de) |
| EP (1) | EP1100480B1 (de) |
| JP (1) | JP2002521429A (de) |
| KR (1) | KR20010079593A (de) |
| CN (1) | CN1157186C (de) |
| AT (1) | ATE250412T1 (de) |
| AU (1) | AU754588B2 (de) |
| BR (1) | BR9912599A (de) |
| CA (1) | CA2339093A1 (de) |
| DE (1) | DE69911620T2 (de) |
| ES (1) | ES2207963T3 (de) |
| WO (1) | WO2000006135A2 (de) |
Families Citing this family (40)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| BRPI0715467A2 (pt) | 2006-07-11 | 2013-03-12 | Refocus Group Inc | pràtese escleral para tratamento de presbiopia e outras doenÇas oculares e dispositivo e mÉtodos relacionados |
| US8911496B2 (en) | 2006-07-11 | 2014-12-16 | Refocus Group, Inc. | Scleral prosthesis for treating presbyopia and other eye disorders and related devices and methods |
| DE602006008643D1 (de) * | 2006-12-18 | 2009-10-01 | Jorge Luis Benozzi | Ophthalmische Zusammensetzungen von parasympathischen Stimulantia und Entzündungshemmer zur Verwendung bei der Behandlung von Presbyopie |
| GB0711151D0 (en) * | 2007-06-11 | 2007-07-18 | Sra Dev Ltd | Switch for use with an ultrasonic surgical tool |
| GB0724558D0 (en) * | 2007-12-15 | 2008-01-30 | Sharma Anant | Optical correction |
| US20100298335A1 (en) * | 2009-05-22 | 2010-11-25 | Kaufman Herbert E | Preparations and Methods for Ameliorating or Reducing Presbyopia |
| US8299079B2 (en) | 2009-05-22 | 2012-10-30 | Kaufman Herbert E | Preparations and methods for ameliorating or reducing presbyopia |
| WO2011075430A1 (en) * | 2009-12-14 | 2011-06-23 | University Of Massachusetts | Methods of inhibiting cataracts and presbyopia |
| US8889735B2 (en) * | 2011-04-07 | 2014-11-18 | Sucampo Ag | Method for treating asthenopia |
| TR201903465T4 (tr) | 2011-09-20 | 2019-04-22 | Allergan Inc | Presbiyopi, hafif hiperopi ve düzensiz astigmatizmin tedavi edilmesine yönelik bileşimler ve yöntemler. |
| AU2014236582B2 (en) | 2013-03-14 | 2018-03-29 | The University Of Massachusetts | Methods of inhibiting cataracts and presbyopia |
| US9314427B2 (en) | 2013-08-28 | 2016-04-19 | Presbyopia Therapies Llc | Compositions and methods for the improvement of distance vision and the treatment of refractive errors of the eye |
| US10064818B2 (en) | 2013-08-28 | 2018-09-04 | Presbyopia Therapies, LLC | Compositions and methods for the treatment of presbyopia |
| US9833441B2 (en) | 2013-08-28 | 2017-12-05 | Presbyopia Therapies Llc | Compositions and methods for the treatment of presbyopia |
| US11179327B2 (en) | 2013-08-28 | 2021-11-23 | Lenz Therapeutics, Inc. | Compositions and methods for the treatment of presbyopia |
| US9844537B2 (en) | 2013-08-28 | 2017-12-19 | Presbyopia Therapies Llc | Compositions and methods for the treatment of presbyopia |
| US9320709B2 (en) | 2013-08-28 | 2016-04-26 | Presbyopia Therapies Llc | Storage stable compositions and methods for the treatment of refractive errors of the eye |
| US10307408B2 (en) | 2013-08-28 | 2019-06-04 | Presbyopia Therapies, LLC | Contact lens compositions and methods for the treatment of presbyopia |
| US10617763B2 (en) | 2013-08-28 | 2020-04-14 | Presbyopia Therapies, LLC | Compositions and methods for the treatment of presbyopia |
| US9968594B2 (en) | 2013-08-28 | 2018-05-15 | Presbyopia Therapies Llc | Compositions and methods for the treatment of presbyopia |
| US9089562B2 (en) * | 2013-08-28 | 2015-07-28 | Presbyopia Therapies Llc | Compositions and methods for the treatment of presbyopia |
| WO2015122853A1 (en) * | 2014-02-11 | 2015-08-20 | Vid D.O.O. | Pharmacological ophthalmic composition for use in the correction of presbyopia and its administration |
| CN107920984A (zh) | 2015-06-18 | 2018-04-17 | 远视眼治疗有限责任公司 | 储存稳定的组合物以及治疗眼睛屈光不正的方法 |
| WO2017083619A1 (en) | 2015-11-13 | 2017-05-18 | The University Of Massachusetts | Bifunctional molecules containing peg for use in inhibiting cataracts and presbyopia |
| CH711969A2 (it) * | 2015-12-29 | 2017-06-30 | Pinelli Roberto | Composizione per il trattamento della presbiopia. |
| JP7297308B2 (ja) | 2016-08-19 | 2023-06-26 | オラシス ファーマシューティカルズ リミティド | 眼科用医薬組成物及びそれに関する使用 |
| SG11202004019SA (en) * | 2017-11-17 | 2020-05-28 | Cellix Bio Private Ltd | Compositions and methods for the treatment of eye disorders |
| BR112020021845A2 (pt) | 2018-04-24 | 2021-02-23 | Allergan, Inc. | tratamentos para presbiopia |
| US20210369686A1 (en) * | 2018-10-06 | 2021-12-02 | Biotheravision Llc | Ophthalmic preparations of muscarinic agonist and methods of use |
| US20210251970A1 (en) | 2018-10-10 | 2021-08-19 | Presbyopia Therapies Inc | Compositions and methods for storage stable ophthalmic drugs |
| CA3114204A1 (en) | 2018-10-10 | 2020-04-16 | Presbyopia Therapies, Inc. | Compositions and methods for the treatment of presbyopia |
| CN110496215A (zh) * | 2019-08-23 | 2019-11-26 | 中国人民解放军总医院 | 一种治疗老视的水性滴眼液及其制备方法 |
| KR20230042077A (ko) * | 2020-09-11 | 2023-03-27 | 인트라투스-네바다, 인크. | 노안, 원시, 난시, 감소된 입체시, 및 감소된 대비 감도를 치료하기 위한 조성물 및 방법 |
| EP4230210A4 (de) * | 2020-10-14 | 2024-10-02 | Santen Pharmaceutical Co., Ltd. | Stabile pharmazeutische zusammensetzung |
| US12180206B2 (en) | 2021-11-17 | 2024-12-31 | Lenz Therapeutics Operations, Inc. | Aceclidine derivatives, compositions thereof and methods of use thereof |
| US11648247B1 (en) | 2021-12-16 | 2023-05-16 | Lenz Therapeutics, Inc. | Compositions and methods for the treatment of presbyopia |
| US20230263727A1 (en) | 2022-01-14 | 2023-08-24 | Somerset Therapeutics, Llc | Ophthalmologically suitable low pka buffer-containing pilocarpine compositions and related methods |
| US11857539B2 (en) | 2022-02-09 | 2024-01-02 | Somerset Therapeutics, Llc | Gel ophthalmic formulations of pilocarpine and brimonidine compounds and related methods |
| KR20240165977A (ko) * | 2022-03-30 | 2024-11-25 | 산텐 세이야꾸 가부시키가이샤 | 의약 제제의 멸균법과 포장체 |
| US12414942B1 (en) | 2024-03-15 | 2025-09-16 | Lenz Therapeutics Operations, Inc. | Compositions, methods, and systems for treating presbyopia |
Family Cites Families (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US5166317A (en) * | 1988-10-31 | 1992-11-24 | Houston Biotechnology Incorporated | Neurotrophic factor |
| FR2638970A1 (fr) | 1988-11-16 | 1990-05-18 | Corbiere Jerome | Nouvelles compositions pharmaceutiques agissant sur la presbytie et leur procede d'obtention |
| US5122522A (en) * | 1989-06-21 | 1992-06-16 | The Trustees Of The University Of Pennsylvania | Treatment and control of ocular development |
| JP3165436B2 (ja) | 1989-06-21 | 2001-05-14 | ザ トラスティーズ オブ ザ ユニバーシティ オブ ペンシルベニア | 眼の発達の治療及び制御 |
| EP0648118A1 (de) | 1992-07-02 | 1995-04-19 | Telor Ophthalmic Pharmaceuticals, Inc. | Verfahren und produkte zur behandlung von altersweitsichtigkeit |
-
1998
- 1998-07-30 US US09/126,064 patent/US6291466B1/en not_active Expired - Lifetime
-
1999
- 1999-07-22 ES ES99937295T patent/ES2207963T3/es not_active Expired - Lifetime
- 1999-07-22 JP JP2000561990A patent/JP2002521429A/ja active Pending
- 1999-07-22 WO PCT/US1999/016260 patent/WO2000006135A2/en not_active Ceased
- 1999-07-22 CN CNB998090514A patent/CN1157186C/zh not_active Expired - Fee Related
- 1999-07-22 AU AU52160/99A patent/AU754588B2/en not_active Ceased
- 1999-07-22 EP EP99937295A patent/EP1100480B1/de not_active Expired - Lifetime
- 1999-07-22 BR BR9912599-4A patent/BR9912599A/pt not_active IP Right Cessation
- 1999-07-22 AT AT99937295T patent/ATE250412T1/de not_active IP Right Cessation
- 1999-07-22 DE DE69911620T patent/DE69911620T2/de not_active Expired - Fee Related
- 1999-07-22 CA CA002339093A patent/CA2339093A1/en not_active Abandoned
- 1999-07-22 KR KR1020017001311A patent/KR20010079593A/ko not_active Ceased
-
2001
- 2001-04-25 US US09/842,299 patent/US6410544B1/en not_active Expired - Lifetime
Also Published As
| Publication number | Publication date |
|---|---|
| CN1311670A (zh) | 2001-09-05 |
| AU754588B2 (en) | 2002-11-21 |
| KR20010079593A (ko) | 2001-08-22 |
| DE69911620D1 (de) | 2003-10-30 |
| CN1157186C (zh) | 2004-07-14 |
| BR9912599A (pt) | 2001-05-02 |
| WO2000006135A2 (en) | 2000-02-10 |
| DE69911620T2 (de) | 2004-07-29 |
| HK1035493A1 (en) | 2001-11-30 |
| JP2002521429A (ja) | 2002-07-16 |
| US6410544B1 (en) | 2002-06-25 |
| WO2000006135A3 (en) | 2000-03-23 |
| EP1100480A2 (de) | 2001-05-23 |
| ES2207963T3 (es) | 2004-06-01 |
| AU5216099A (en) | 2000-02-21 |
| EP1100480B1 (de) | 2003-09-24 |
| US6291466B1 (en) | 2001-09-18 |
| CA2339093A1 (en) | 2000-02-10 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| ATE250412T1 (de) | Muskarinische antagonisten zur behandlung von presbyopie | |
| ATE207356T1 (de) | Verwendung von tiagabin zur behandlung von schlafstörungen | |
| ATE320803T1 (de) | Verfahren zur behandlung von alzheimerschen krankheit | |
| DE69739792D1 (de) | Verfahren zur Behandlung von Augenerkrankungen | |
| NO992755D0 (no) | Protese for °yets senehinne for behandling av presbyopi og andre forstyrrelser i °yner | |
| BR0007699A (pt) | Métodos para restaurar e/ou melhorar a acomodação de pseudofaquia | |
| DE69805973D1 (de) | Behandlung von herzrythmusstörungen durch hemmung einer multifunktionalen calcium/calmodulin-abhängigen protein kinase | |
| DE10199020I2 (de) | Galanthamin oder dessen Analoge zur Behandlung derAlzheimerschen Krankheit. | |
| ATE361752T1 (de) | Methoden zur prophylaxe und behandlung von schäden der wahrnehmungshärchenzellen und der cochlearen neuronen | |
| NZ334063A (en) | use of a combination of a histamine H1 receptor antagonist and a histamine H3 receptor antagonist to treat upper airway allergic responses | |
| MY112973A (en) | Methods for inhibiting vascular smooth muscle cell migration | |
| ATE453402T1 (de) | Verwendung von serp-1 in kombination mit einem immunosuppressor zur behandlung von arthritis | |
| DE69927380D1 (de) | Oxazolidinones zur behandlung von augeninfektionen | |
| DE69613041D1 (de) | Verwendung von Erdalkalimetalsalzen in Mitteln zur Behandlung van Augen- oder Augenlidschmerzen oder Dysesthesien | |
| DE59907195D1 (de) | Verfahren zur behandlung von erkrankungen oder störungen des innenohrs | |
| ATE294584T1 (de) | Verwendung von desoxypeganin zur behandlung von alzheimerischer demenz | |
| PT1007093E (pt) | Metodos para o tratamento de desordens atraves da utilizacao de interleucina-9 e seus antagonistas | |
| DE69733557D1 (de) | Endothelin-antagonisten zur behandlung von herzversagen | |
| ATE222768T1 (de) | Ctla-8 in kombination mit g-csf oder mit g-csf und il-6, und verwendung vom ctla-8 zur behandlung von infektionen | |
| EP0329948A3 (de) | Verwendung von Betablockern zur Behandlung der Progression der kindlichen Achsenmyopie | |
| ATE262362T1 (de) | Verwendung von cyamemazin zur behandlung von entwöhnungserscheinungen der benzodiazepinbehandlung | |
| ATE369143T1 (de) | Verwendung von ngali nussöl zur behandlung/linderung der arthritisschmerzen und anderer ähnlichen störungen | |
| NO984196D0 (no) | Fremgangsmåte for behandling av stoffmisbruk | |
| DE69635282D1 (de) | Behandlung der exzessiven aggressivität mit olanzapine | |
| ATE345138T1 (de) | Verfahren und zusammensetzungen zur vorbeugung und behandlung von sodbrennen |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| RER | Ceased as to paragraph 5 lit. 3 law introducing patent treaties |